{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-055420","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2021-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.427265+00:00","generated_at":"2026-06-28T16:10:22.771900+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CorMedix CFO Matt David appointed interim CEO; salary to $425k, bonus 60%","bullets":["Dr. David's base salary rises from $330k to $425k during interim CEO period; after, it resets to $375k.","Target annual bonus increased to 60% of base salary while interim CEO; thereafter 40%.","Severance extended to 12 months of base salary if terminated without cause during interim CEO role.","Board grants Dr. David a stock option for 125,000 shares, vesting over four years.","Board has initiated search with a leading executive firm for a permanent CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-055420","json":"https://secwatch.observer/filing/0001213900-21-055420.json","markdown":"https://secwatch.observer/filing/0001213900-21-055420.md","text":"https://secwatch.observer/filing/0001213900-21-055420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021055420/0001213900-21-055420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021055420/ea149576-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:10:22.771900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7770627145","claim":"Matt David was appointed as interim Chief Executive Officer at CorMedix Inc..","evidence_excerpt":"On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021055420/0001213900-21-055420-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}